Ernexa Therapeutics Inc. Accounts Receivable
Ernexa Therapeutics Inc. (ERNA) had Accounts Receivable of $684.00 thousand as of 2021-12-31, per its 10-K/A filed 2022-07-01.
Discontinued › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2022-07-01
- 2021-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $684.00K.
- 2021-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $24.92K.
- 2020-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $0.00; Accounts Receivable, after Allowance for Credit Loss, Current as first filed $116.00K.
- 2020-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $132.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2021-12-31 | $684.00K 10-K/A · filed 2022-07-01 | |
| 2021-03-31 | $24.92K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $0.00 10-K/A · filed 2022-07-01 | $116.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $132.00K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $186.00K 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $383.00K 10-Q · filed 2020-05-20 | |
| 2019-12-31 | $1.20M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $777.00K 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $732.00K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $848.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $1.14M 10-K · filed 2020-03-19 | |
| 2018-09-30 | $1.28M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $787.00K 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $1.03M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $714.00K 10-K · filed 2019-03-22 | |
| 2017-09-30 | $627.00K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $761.00K 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $1.76M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $928.00K 10-K · filed 2018-03-09 | |
| 2016-09-30 | $898.00K 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $641.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $769.00K 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $919.00K 10-K · filed 2017-03-09 | |
| 2014-12-31 | $2.19M 10-K · filed 2016-03-15 | |
| 2013-12-31 | $641.00K 10-K · filed 2015-03-27 | |
| 2013-03-31 | $573.00K 10-Q · filed 2013-05-13 | |
| 2012-12-31 | $610.00K 10-Q · filed 2013-05-13 | |
| 2012-09-30 | $1.09M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $640.00K 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $662.00K 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $750.00K 10-K · filed 2013-03-29 | |
| 2011-09-30 | $516.00K 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $475.00K 10-Q · filed 2011-08-12 | |
| 2010-12-31 | $549.00K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |